Menu

Exploring Targeted Therapy for Non-Small Cell Lung Cancer

Rutgers Cancer Institute researcher awarded grant to explore gene mutation that drives tumors
January 24, 2019

New Brunswick, N.J. – Rutgers Cancer Institute of New Jersey researcher Sharon R. Pine, PhD, has received a $200,000 Lung Cancer Discovery Award from the American Lung Association to examine potential new treatment options for patients with a sub-type of non-small cell lung cancer.

Lung cancer remains the leading cause of cancer death for both men and women in the United States and non-small cell lung cancer accounts for 86 percent of these cases, according to National Cancer Institute Surveillance, Epidemiology, and End Results Program data. Squamous cell carcinoma is a type of non-small cell lung cancer. Most patients with lung cancer are diagnosed after the cancer has already spread and options for therapy are very few. There are still no targeted therapies available for most patients with lung squamous cell carcinoma.

In this project funded by the American Lung Association, Dr. Pine aims to test a novel way to treat squamous cell carcinomas that have a mutation in the gene known as PIK3CA. A mutation in PIK3CA is believed to be the "driver" of this type of non-small cell lung cancer tumor. Pine and colleagues will conduct pre-clinical pilot studies to examine potential new treatment options for patients whose cancer has this mutation.

“Precision medicine is fundamentally about providing a complete characterization of cancer subtypes at the molecular level and matching them with the most efficient and least toxic drugs, in order to improve survival for our patients,” notes Pine, who is also an associate professor of pharmacology and medicine at Rutgers Robert Wood Johnson Medical School.

The project period runs through December 2020.

About Rutgers Cancer Institute of New Jersey

As New Jersey’s only National Cancer Institute-designated Comprehensive Cancer Center, Rutgers Cancer Institute, along with its partner RWJBarnabas Health, offers the most advanced cancer treatment options including bone marrow transplantation, proton therapy and CAR-T cell therapy.  Along with clinical trials and novel therapeutics such as precision medicine and immunotherapy – many of which are not widely available – patients have access to these cutting-edge therapies at Rutgers Cancer Institute of New Jersey in New Brunswick, Rutgers Cancer Institute of New Jersey at University Hospital in Newark, as well as through RWJBarnabas Health facilities.

Along with world-class treatment, which is often fueled by on-site research conducted in Rutgers Cancer Institute laboratories, patients and their families also can seek cancer preventative services and education resources throughout the Rutgers Cancer Institute and RWJBarnabas Health footprint statewide. To make a tax-deductible gift to support the Cancer Institute of New Jersey, call 848-932-8013 or visit www.cinj.org/giving.

About the American Lung Association in New Jersey

The American Lung Association in New Jersey is the leading organization working to save lives by improving lung health and preventing lung disease, through research, education and advocacy. The work of the American Lung Association in New Jersey is focused on four strategic imperatives: to defeat lung cancer; to improve the air we breathe; to reduce the burden of lung disease on individuals and their families; and to eliminate tobacco use and tobacco-related diseases. For more information about the American Lung Association in New Jersey, a holder of the Better Business Bureau Wise Giving Guide Seal, or to support the work it does, call 1-800-LUNGUSA (1-800-586-4872) or visit:  Lung.org.

About LUNG FORCE

LUNG FORCE is a new national movement led by the American Lung Association to unite women against lung cancer, the #1 cancer killer of women. LUNG FORCE has three priorities: 1) Make lung cancer a cause that people care about – and act on; 2) Educate and empower patients and healthcare providers and 3) Raise critical funds for lung cancer research. The American Lung Association's LUNG FORCE is nationally presented by CVS Health. Find out more at LUNGFORCE.org.

###

For journalists – contact:

Michele Fisher, Public Relations Manager

732-235-9872

michele.fisher@rutgers.edu

For patient appointments/inquiries – contact:

732-235-8515

 

 

 

 

 

ScreenNJ

 

 

 

precision medicine at Rutgers Cancer Institute

 

 

 


 

 

 

 

Proud member of
Big Ten Cancer Research Consortium

 

 

Rutgers Health